Longitudinal Evaluation of Hip Cartilage Degeneration: the effect of Femoroacetabular Impingement

IRB Number: 14171

Institutional Review Board, Hospital for Special Surgery

April 24, 2015

The safety of study participants is our top priority. The trial is approved and periodically reviewed by an Institutional Review Board (IRB), which includes doctors, administrators, ethicists, and members of the general public. The safety of clinical trials is reviewed by the U.S. Food and Drug Administration.

Before enrolling in a clinical trial, the investigator will explain the purpose of the trial, its expected benefits, any possible risks or side effects, and what your role will be. This is the time to ask questions! If you want to join the trial, you must sign the informed consent documents. You can leave a clinical trial at any time without penalty.

For further information, see Understanding Clinical Trials.

Principal Investigator

Stephen Lyman, PhD


Bryan T Kelly, MD
Robert G. Marx, MD, MSc, FRCSC
Hollis G. Potter, MD
Matthew F. Koff, PhD
Danyal H. Nawabi, MD, FRCS
Stephanie Mayer, MD
Kara Fields, MS
Catherine Wentzel, BS
Naomi Wagner, BA


Femoroacetabular impingement (FAI) is one of the most common mechanisms leading to the development of early cartilage and labral damage in the non-dysplastic hip.  Anatomic abnormalities of the proximal femur and/or acetabulum result in repetitive injury during dynamic hip motion, leading to abnormal regional loading of the femoral head-neck junction against the acetabular rim.  The resulting damage to the cartilage, labrum, and surrounding capsular structures predispose the patient to developing hip pain and early osteoarthritic changes.  Clinically, patients with FAI are a heterogeneous group, with a wide array of presentation from pain to instability that may or may not be related to activity.  To date no studies have identified specific prognostic indicators associated with successful surgical treatment of FAI, leaving surgeons without adequate criteria to determine which patients are best suited for arthroscopy.  We propose to address this critical knowledge gap by identifying the patient characteristics and morphological features of the hip that are associated with the optimal clinical outcomes in patients undergoing hip arthroscopy or non-operative management for treatment of suspected FAI in order to establish a treatment algorithm for FAI patients.

Inclusion/Exclusion Criteria

Inclusion criteria:

All patients 35 years of age or younger enrolled in the HSS Hip Preservation Registry prior to September 30, 2016 with an MRI confirmed diagnosis of FAI will be eligible for inclusion in this study regardless of surgery status.

Patients who agree to participate must complete a baseline questionnaire consisting of: a) Modified Harris Hip Score (MHHS), an overall measure of hip condition; b) the Hip Outcome Score (HOS), a measure developed specifically for younger active patients that measure quality of life and levels of sports and recreation; and c) International Hip Outcome Tool, a newly developed hip specific outcome score, which measures a number of subscores relating to physical and social functioning with hip problems.

Exclusion criteria:

Patients over age 35 will be exclused as the focus of this study is early changes that may predispose to later degenerative changes.  Patients undergoing revision hip arthroscopy as their first treatment in the Registry will not be eligible, as these are patients who have failed initial therapy.  Patients with no complete questionnaires at any time point will be excluded.

Contact Information

Stephen Lyman, PhD